Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.

Published on Mar 1, 2017in Graefes Archive for Clinical and Experimental Ophthalmology2.396
· DOI :10.1007/S00417-016-3489-5
Joo Eun Lee15
Estimated H-index: 15
(Inje University),
Jae Pil Shin2
Estimated H-index: 2
(Kyungpook National University Hospital)
+ 5 AuthorsJi Eun Lee19
Estimated H-index: 19
(PNU: Pusan National University)
Purpose To investigate fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy (PCV).
📖 Papers frequently viewed together
393 Citations
#1Akiko Yamamoto (Kyorin University)H-Index: 6
#2Annabelle A. Okada (Kyorin University)H-Index: 30
Last. Tomohiro IidaH-Index: 53
view all 8 authors...
Purpose To investigate 1-year outcomes of intravitreal aflibercept for polypoidal choroidal vasculopathy (PCV). Design Retrospective, multicenter, consecutive case series. Participants A total of 90 eyes of 87 patients with treatment-naive PCV followed at 3 tertiary centers. Methods Clinical records were reviewed and imaging studies were analyzed of eyes with PCV that underwent 3 consecutive monthly aflibercept injections followed by injections every 2 months. Additional (rescue) injections were...
88 CitationsSource
#1Mio Hosokawa (Okayama University)H-Index: 11
#2Fumio Shiraga (Okayama University)H-Index: 14
Last. Yuki Morizane (Okayama University)H-Index: 6
view all 12 authors...
Background This study aims to evaluate the therapeutic effect of intravitreal aflibercept injection for polypoidal choroidal vasculopathy (PCV). Methods Eighteen eyes of 17 consecutive patients with PCV received three consecutive monthly intravitreal injections of aflibercept and one additional injection 2 months later (four injections totally). All patients underwent eye examinations, which included best-corrected visual acuity (BCVA), fluorescein angiography, indocyanine green angiography, and...
19 CitationsSource
#1Akio Oishi (Kyoto University)H-Index: 38
#2Akitaka Tsujikawa (Kyoto University)H-Index: 60
Last. Nagahisa Yoshimura (Kyoto University)H-Index: 89
view all 14 authors...
Purpose To investigate the efficacy of periodic injection of aflibercept in each subtype of age-related macular degeneration (AMD) and to explore the predictive factors for visual outcome in clinical settings. Design Prospective nonrandomized interventional case series. Methods Patients with AMD were recruited and were administered aflibercept injections once a month for 3 months followed by once every 2 months for 8 months. The logarithm of the minimal angle of resolution (logMAR) at 12 months ...
77 CitationsSource
Purpose:To evaluate the functional and morphologic outcomes of patients with polypoidal choroidal vasculopathy who underwent intravitreal aflibercept treatment.Methods:We prospectively studied all the treatment-naive patients with polypoidal choroidal vasculopathy who were scheduled to undergo intra
43 CitationsSource
#1Ik Soo ByonH-Index: 13
#2Han Jo KwonH-Index: 9
Last. Ji Eun LeeH-Index: 19
view all 6 authors...
Abstract To evaluate the effect of reduced-fluence photodynamic therapy (PDT) on polypoidal choroidal vasculopathy (PCV) unresponsive to intravitreal ranibizumab. Patients with PCV unresponsive to ranibizumab administered 3 months consecutively who then received reduced-fluence PDT were retrospectively surveyed. Nonresponders were defined as patients having no reduction in intraretinal and/or subretinal fluid after 3 consecutive treatments. In total, 22 of 104 eyes (21.2%) were non-responders, a...
8 CitationsSource
#1Akio OishiH-Index: 38
#2Hiroshi KojimaH-Index: 13
Last. Akira Negi (Kobe University)H-Index: 45
view all 13 authors...
Purpose To compare the effect of photodynamic therapy (PDT) and intravitreal ranibizumab in patients with polypoidal choroidal vasculopathy (PCV). Design Randomized clinical trial. Methods setting: Multicenter. study population: Total of 93 patients with treatment-naive PCV. intervention: Patients were randomized to 2 arms. Patients in the PDT arm underwent a single session of PDT with verteporfin, and patients in the ranibizumab arm received 3 monthly ranibizumab injections at baseline. Additio...
105 CitationsSource
#1Maiko Inoue (Yokohama City University Medical Center)H-Index: 21
#2Akira Arakawa (Yokohama City University Medical Center)H-Index: 19
Last. Kazuaki Kadonosono (Yokohama City University Medical Center)H-Index: 29
view all 4 authors...
Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy
27 CitationsSource
Background:Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy affecting vision, with clinical features distinct from neovascular age-related macular degeneration. Currently, no evidence-based guidelines exist for its diagnosis and treatment.Methods:A panel of experts analyzed a syst
189 CitationsSource
#1Jeffrey S. Heier (Tufts University)H-Index: 57
#2David M. BrownH-Index: 46
Last. Ursula Schmidt-Erfurth (Medical University of Vienna)H-Index: 89
view all 20 authors...
Objective Two similarly designed, phase-3 studies (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD [VIEW 1, VIEW 2]) of neovascular age-related macular degeneration (AMD) compared monthly and every-2-month dosing of intravitreal aflibercept injection (VEGF Trap-Eye; Regeneron, Tarrytown, NY, and Bayer HealthCare, Berlin, Germany) with monthly ranibizumab. Design Double-masked, multicenter, parallel-group, active-controlled, randomized trials. Participants Patients (n = 2419) with ...
1,383 CitationsSource
Purpose:To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.Methods:In this multicenter, double-masked, primarily indocyanine green angiography–guided
393 CitationsSource
Cited By34
#1Voraporn Chaikitmongkol (CMU: Chiang Mai University)H-Index: 11
#2Phit Upaphong (CMU: Chiang Mai University)H-Index: 2
Last. Neil M. Bressler (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 93
view all 12 authors...
PURPOSE To understand timing of complete polypoidal regression on indocyanine green angiography (ICGA) after aflibercept injections in polypoidal choroidal vasculopathy (PCV). DESIGN Multicenter prospective study PARTICIPANTS: Adults with treatment-naive PCV METHODS: After IRB approval, participants were enrolled and followed for 1 year, Apr 1, 2016 to Dec 30, 2018 at two university-based centers in Thailand. PCV diagnosis was based on the EVEREST criteria. Eligible eyes received fixed-dosing af...
1 CitationsSource
INTRODUCTION There are a few reports investigating the treatment of aneurysmal type 1 neovascularization (AT1) in Caucasian patients. The aim of this study is to evaluate the 2-year results of a treat and extend regimen with aflibercept in Caucasian patients with AT1. METHODS We conducted an observational retrospective study in 28 eyes of 26 patients with naive AT1 treated with a treat an extend regimen of intravitreal aflibercept. Best corrected visual acuity (BCVA), central macular thickness (...
#1Mengxi Shen (UM: University of Miami)H-Index: 2
#1Mengxi Shen (UM: University of Miami)H-Index: 2
Last. Philip J. Rosenfeld (UM: University of Miami)H-Index: 84
view all 9 authors...
Abstract Purpose To investigate the morphological changes of polyps in eyes with polypoidal choroidal vasculopathy (PCV) after treatment with vascular endothelial growth factor (VEGF) inhibitors using swept source optical coherence tomography angiography (SS-OCTA). Observations Following anti-VEGF therapy, polyps were found to evolve into typical type 1 macular neovascularization (MNV) in five eyes. In all of these five eyes, a polypoidal lesion was detected adjacent to a serous or hemorrhagic r...
#1Hun Gu Choo (Yonsei University)
#2Jin Hae LeeH-Index: 3
Last. Oh Woong KwonH-Index: 27
view all 6 authors...
BACKGROUND Polypoidal choroidal vasculopathy (PCV) is a type of age-related macular degeneration that can cause permanent vision loss. The purpose of this paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for the treatment of PCV. METHODS This was a prospective, single-arm, interventional case series study of 25 PCV patients; 12 pre-treated and 13 treatment-naive patients. The patients were treated and monitored for 12 months. Each patient was administered with an afl...
#1Ji Min KwonH-Index: 2
#2Kang Yeun PakH-Index: 7
Last. Hyun Woong KimH-Index: 14
view all 5 authors...
Purpose To evaluate the one-year efficacy of intravitreal aflibercept injection in polypoidal choroidal vasculopathy (PCV) with best-corrected visual acuity (BCVA) of 20/40 or better. Methods This was a multicenter retrospective study. The medical records of patients diagnosed with treatment-naive PCV were retrospectively reviewed. Patients with an initial BCVA of 20/40 or better and who had undergone intravitreal aflibercept injection were included. Patients were treated with 3 consecutive mont...
#1Sheng-Chu Chi (Taipei Veterans General Hospital)
#2Yi No Kang (TMU: Taipei Medical University)H-Index: 9
Last. Yi-Ming Huang (NYMU: National Yang-Ming University)H-Index: 3
view all 3 authors...
Polypoidal choroidal vasculopathy (PCV) is a vision-threatening disease common in Asian populations. However, the optimal treatment for PCV remains under debate. We searched the databases with optimal searching strategy. The study included randomized clinical trials and prospective studies that recruited patients with active PCV who had received interventions, including PDT, anti-VEGF, or a combination of PDT and anti-VEGF. The Grading of Recommendations Assessment, Development, and Evaluation m...
#1Yuichiro Ogura (Nagoya City University)H-Index: 52
#2Tomohiro IidaH-Index: 53
Last. Tatsuro Ishibashi (Kyushu University)H-Index: 77
view all 8 authors...
PURPOSE To evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) versus IVT-AFL plus rescue photodynamic therapy (IVT-AFL + rPDT) in the subgroup of Japanese patients with polypoidal choroidal vasculopathy (PCV) enrolled in the PLANET study. STUDY DESIGN A 96-week, double-masked, sham-controlled phase-3b/4 randomized clinical trial conducted at multiple centers from May 2014 to August 2016. PATIENTS AND METHODS Patients with PCV (BCVA 73-24 ETDRS letters [20/40-20/320 Snellen]) ...
#1Weisen Wang (RUC: Renmin University of China)H-Index: 2
#2Xirong Li (RUC: Renmin University of China)H-Index: 29
Last. Youxin ChenH-Index: 13
view all 7 authors...
This paper tackles automated categorization of Age-related Macular Degeneration (AMD), a common macular disease among people over 50. Previous research efforts mainly focus on AMD categorization with a single-modal input, let it be a color fundus image or an OCT image. By contrast, we consider AMD categorization given a multi-modal input, a direction that is clinically meaningful yet mostly unexplored. Contrary to the prior art that takes a traditional approach of feature extraction plus classif...
#1Ai Yoneda (Nagasaki University)H-Index: 1
#2Harumi Wakiyama (Nagasaki University)H-Index: 2
Last. Takashi Kitaoka (Nagasaki University)H-Index: 19
view all 4 authors...
Purpose:To compare the 2-year outcomes of combination therapy using intravitreal ranibizumab and photodynamic therapy with those of fixed-dosing intravitreal aflibercept monotherapy as initial trea...
1 CitationsSource
#1Tomoko Tamachi (OCU: Osaka City University)
#2Takeya Kohno (OCU: Osaka City University)H-Index: 12
Last. Shigeru Honda (OCU: Osaka City University)H-Index: 3
view all 9 authors...
To evaluate 1-year outcomes of intravitreal aflibercept (IVA) using a treat-and-extend (TAE) regimen for polypoidal choroidal vasculopathy (PCV) and identify the factors for patients whose treatment intervals could be extended. Fifty-one eyes of treatment-naive PCV patients treated with IVA using a TAE regimen for at least 1 year were examined retrospectively. All patients received at least three IVA injections every 5 weeks, and the intervals were then extended by 2-week adjustments up to 13 we...
1 CitationsSource